samedi 18 novembre 2017
vendredi 17 novembre 2017
Cannabis and violence: when the brain dysfunctions
https://www.frontiersin.org/articles/10.3389/fpsyt.2017.00176/full
Toujours les IJ
http://www.leprogres.fr/france-monde/2017/11/15/absenteisme-des-fonctionnaires-territoriaux-28-en-dix-ans
https://inflib.com/deficit-de-la-secu-labsenteisme-du-personnel-dans-les-organismes-de-securite-sociale-coute-370-millions-deuros-par-an/
http://www.lefigaro.fr/conjoncture/2010/09/08/04016-20100908ARTFIG00533-la-securite-sociale-souffre-d-un-absenteisme-eleve.php
https://www.sofaxis.com/sites/default/files/publications/pdfs/regard_sur_tend2015_territorial_r2556.pdf
https://inflib.com/deficit-de-la-secu-labsenteisme-du-personnel-dans-les-organismes-de-securite-sociale-coute-370-millions-deuros-par-an/
http://www.lefigaro.fr/conjoncture/2010/09/08/04016-20100908ARTFIG00533-la-securite-sociale-souffre-d-un-absenteisme-eleve.php
https://www.sofaxis.com/sites/default/files/publications/pdfs/regard_sur_tend2015_territorial_r2556.pdf
jeudi 16 novembre 2017
The roots of terror
" La Révolution m'aurait entraîné, si elle n'eût débuté par des crimes : je vis la première tête portée au bout d'une pique , et je reculai. Jamais le meurtre ne sera à mes yeux un objet d'admiration et un argument de liberté ; je ne connais rien de plus servile, de plus méprisable, de plus lâche , de plus borné qu'un terroriste."
Chateaubriand
Before the German-Soviet pact of Ribbentrop and Molotov, the roots of cooperation between the two totalitarianisms
https://en.wikipedia.org/wiki/Lipetsk_fighter-pilot_school
https://en.wikipedia.org/wiki/Treaty_of_Rapallo_(1922)
One must read this paper:
https://www.jstor.org/stable/1986524?seq=1#page_scan_tab_contents
also:
http://avalon.law.yale.edu/20th_century/rapallo_001.asp
The "forgotten" story of the links between communism and Nazism.
https://en.wikipedia.org/wiki/Treaty_of_Rapallo_(1922)
One must read this paper:
https://www.jstor.org/stable/1986524?seq=1#page_scan_tab_contents
also:
http://avalon.law.yale.edu/20th_century/rapallo_001.asp
The "forgotten" story of the links between communism and Nazism.
Orwell
"Connaître et ne pas connaître. En pleine conscience et avec une absolue bonne foi, émettre des mensonges soigneusement agencés. Retenir simultanément deux opinions qui s’annulent alors qu’on les sait contradictoires et croire à toutes deux. Employer la logique contre la logique. Répudier la morale alors qu’on se réclame d’elle. Oublier tout ce qu’il est nécessaire d’oublier, puis le rappeler à sa mémoire quand on en a besoin, pour l’oublier plus rapidement encore". George Orwell, 1984.
mercredi 15 novembre 2017
PAD: association of NOCA and aspirin is efficient despite a higher risk of bleeding
COMPASS
COMPASS PAD: Among 7,470 participants with peripheral arterial disease (PAD), 4,129 had symptomatic PAD, 1,919 had carotid disease, and 1,422 had coronary artery disease plus ankle-brachial index <0 .9.="" br="">
Major adverse cardiac events (MACE): 5.1% for rivaroxaban plus aspirin, 6.0% for rivaroxaban alone, vs. 6.9% for aspirin alone (p = 0.005 for rivaroxaban plus aspirin vs. aspirin alone; p = 0.19 for rivaroxaban alone vs. aspirin alone)
Major adverse limb events: 6.3% for rivaroxaban plus aspirin, 7.6% for rivaroxaban alone, vs. 9.0% for aspirin alone (p = 0.0003 for rivaroxaban plus aspirin vs. aspirin alone; p = 0.08 for rivaroxaban alone vs. aspirin alone)
Major bleeding: 3.1% for rivaroxaban plus aspirin, 3.2% for rivaroxaban alone, vs. 1.9% for aspirin alone (p = 0.009 for rivaroxaban plus aspirin vs. aspirin alone; p = 0.004 for rivaroxaban alone vs. aspirin alone)
Study Design
Randomized
Parallel
Blinded
Patients with stable atherosclerosis were randomized to rivaroxaban 2.5 mg twice daily plus aspirin (n = 9,152) vs. rivaroxaban alone (n = 9,117) vs. aspirin alone (n = 9,126).
Total number of enrollees: 27,395
Duration of follow-up: mean 23 months
Mean patient age: 68 years
Percentage female: 23%
Percentage with diabetes: 38%
Inclusion criteria:
Atherosclerosis in ≥2 vascular beds or two additional risk factors (current smoking, diabetes, renal insufficiency, heart failure, or nonlacunar ischemic stroke ≥1 month)
Exclusion criteria:
High bleeding risk
Recent stroke or previous hemorrhagic or lacunar stroke
Severe heart failure
Advanced kidney disease
Use of dual antiplatelet therapy or anticoagulation
Limited prognosis
Principal Findings:
The primary outcome, incidence of cardiovascular death, myocardial infarction, or stroke, occurred in 4.1% of the rivaroxaban plus aspirin group vs. 4.9% of the rivaroxaban alone group vs. 5.4% of the aspirin alone group (p < 0.001 for rivaroxaban plus aspirin vs. aspirin alone; p = 0.12 for rivaroxaban alone vs. aspirin alone). The primary efficacy outcome was the same in all tested subgroups.
Secondary outcomes:
All-cause mortality: 3.4% for rivaroxaban plus aspirin, 4.0% for rivaroxaban alone, vs. 4.1% for aspirin alone (p = 0.01 for rivaroxaban plus aspirin vs. aspirin alone; p = 0.67 for rivaroxaban alone vs. aspirin alone)
Stroke: 0.9% for rivaroxaban plus aspirin, 1.3% for rivaroxaban alone, vs. 1.6% for aspirin alone (p < 0.001 for rivaroxaban plus aspirin vs. aspirin alone; p = 0.12 for rivaroxaban alone vs. aspirin alone)
Major bleeding: 3.1% for rivaroxaban plus aspirin, 2.8% for rivaroxaban alone, vs. 1.9% for aspirin alone (p < 0.001 for rivaroxaban plus aspirin vs. aspirin alone, p < 0.001 for rivaroxaban alone vs. aspirin alone)
 |
| COMPASS study |
COMPASS PAD: Among 7,470 participants with peripheral arterial disease (PAD), 4,129 had symptomatic PAD, 1,919 had carotid disease, and 1,422 had coronary artery disease plus ankle-brachial index <0 .9.="" br="">
Major adverse cardiac events (MACE): 5.1% for rivaroxaban plus aspirin, 6.0% for rivaroxaban alone, vs. 6.9% for aspirin alone (p = 0.005 for rivaroxaban plus aspirin vs. aspirin alone; p = 0.19 for rivaroxaban alone vs. aspirin alone)
Major adverse limb events: 6.3% for rivaroxaban plus aspirin, 7.6% for rivaroxaban alone, vs. 9.0% for aspirin alone (p = 0.0003 for rivaroxaban plus aspirin vs. aspirin alone; p = 0.08 for rivaroxaban alone vs. aspirin alone)
Major bleeding: 3.1% for rivaroxaban plus aspirin, 3.2% for rivaroxaban alone, vs. 1.9% for aspirin alone (p = 0.009 for rivaroxaban plus aspirin vs. aspirin alone; p = 0.004 for rivaroxaban alone vs. aspirin alone)
Study Design
Randomized
Parallel
Blinded
Patients with stable atherosclerosis were randomized to rivaroxaban 2.5 mg twice daily plus aspirin (n = 9,152) vs. rivaroxaban alone (n = 9,117) vs. aspirin alone (n = 9,126).
Total number of enrollees: 27,395
Duration of follow-up: mean 23 months
Mean patient age: 68 years
Percentage female: 23%
Percentage with diabetes: 38%
Inclusion criteria:
Atherosclerosis in ≥2 vascular beds or two additional risk factors (current smoking, diabetes, renal insufficiency, heart failure, or nonlacunar ischemic stroke ≥1 month)
Exclusion criteria:
High bleeding risk
Recent stroke or previous hemorrhagic or lacunar stroke
Severe heart failure
Advanced kidney disease
Use of dual antiplatelet therapy or anticoagulation
Limited prognosis
Principal Findings:
The primary outcome, incidence of cardiovascular death, myocardial infarction, or stroke, occurred in 4.1% of the rivaroxaban plus aspirin group vs. 4.9% of the rivaroxaban alone group vs. 5.4% of the aspirin alone group (p < 0.001 for rivaroxaban plus aspirin vs. aspirin alone; p = 0.12 for rivaroxaban alone vs. aspirin alone). The primary efficacy outcome was the same in all tested subgroups.
Secondary outcomes:
All-cause mortality: 3.4% for rivaroxaban plus aspirin, 4.0% for rivaroxaban alone, vs. 4.1% for aspirin alone (p = 0.01 for rivaroxaban plus aspirin vs. aspirin alone; p = 0.67 for rivaroxaban alone vs. aspirin alone)
Stroke: 0.9% for rivaroxaban plus aspirin, 1.3% for rivaroxaban alone, vs. 1.6% for aspirin alone (p < 0.001 for rivaroxaban plus aspirin vs. aspirin alone; p = 0.12 for rivaroxaban alone vs. aspirin alone)
Major bleeding: 3.1% for rivaroxaban plus aspirin, 2.8% for rivaroxaban alone, vs. 1.9% for aspirin alone (p < 0.001 for rivaroxaban plus aspirin vs. aspirin alone, p < 0.001 for rivaroxaban alone vs. aspirin alone)
Open data à partir du SNIIRAM: ADO versus AVK
https://www.cardiologie-pratique.com/axistv/video/aod-versus-avk-aod-conteste
Nicholas Moore
Les résultats sont "encore mieux que dans les essais cliniques"...
Non. Les essais clinique suffisent.
Nicholas Moore
Les résultats sont "encore mieux que dans les essais cliniques"...
Non. Les essais clinique suffisent.
mardi 14 novembre 2017
Glyphosate does not cause cancer
Science is not believing. Science is about facts.
 |
| This has never been done for an herbicide at such scale |
lundi 13 novembre 2017
There's no stimulus free lunch
It's hard to spend wisely and spend fast.
http://ac.matra.free.fr/FB/stimulusbecker.pdf
Keep in mind that the so-called "multiplier" is not different from zero as bob Barrow said it.
.
https://www.forbes.com/sites/nickschulz/2011/10/04/yes-there-is-such-thing-as-a-free-lunch-its-called-immigration/#41415afe6edc
How to open selectively the doors to high skilled immigrants?
http://ac.matra.free.fr/FB/stimulusbecker.pdf
Keep in mind that the so-called "multiplier" is not different from zero as bob Barrow said it.
.
https://www.forbes.com/sites/nickschulz/2011/10/04/yes-there-is-such-thing-as-a-free-lunch-its-called-immigration/#41415afe6edc
How to open selectively the doors to high skilled immigrants?